Screener / SEC EDGAR /CIK 0001723128 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Amneal Pharmaceuticals, Inc. AMRX

Compare with peers Embed
The 10-K against last year's

166 changes: 24 added, 16 removed, 117 reworded, 9 quiet changes

10-K Feb 27, 2026 vs Feb 28, 2025

10-K 0001723128-26-000011 (Feb 27, 2026) vs 10-K 0001723128-25-000012 (Feb 28, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

201 paragraphs · 11 new · 84 reworded · 6 gone · 10-K Feb 27, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 8 · 50% changed Every version of it
•our ability •scaling-up manufacturing to scale-up manufacturing methods to successfully manufacture commercial quantities of drug product meet demand in compliance with regulatory requirements.
Paragraph 78 · 49% changed Every version of it
We may seek to expand our business through complementary or strategic acquisitions of other businesses, products or assets, or through joint ventures, strategic agreements or other arrangements. Any such acquisitions, joint ventures or other business combinations may involve significant integration challenges, operational complexities and time consumption, adversely affect liquidity and require substantial resources and effort. It may also disrupt our ongoing businesses, which may adversely affect our relationships with customers, employees, regulators and others with whom we conduct business. Further, if we are unable to realize synergies or other benefits expected to result from any acquisitions, joint ventures or other business combinations, or to generate additional revenue to offset any unanticipated inability to realize these expected synergies or benefits, our growth and ability to compete may be impaired, which would require us to focus additional resources on the integration of operations rather than other profitable areas of our business, and may otherwise cause a material adverse effect on our business, results of operations and financial condition. Acquisitions may also have hidden costs, including unforeseen pre-acquisition liabilities or the impairment of customer relationships or certain acquired assets such as goodwill. We may also incur costs and inefficiencies to the extent an acquisition expands the industries, markets or geographies in which we operate due to our limited exposure to and experience in a given industry, market or region. Finally, acquisitions can also involve litigation and/or post-transaction disputes, including with the counterparty regarding purchase price or other working capital adjustment or liabilities for which we believe we were indemnified under the relevant transaction agreements, among other matters.
Paragraph 135 · 45% changed Every version of it
take a position contrary to a position that we have taken and may impose civil and/or criminal sanctions on us. Any such penalties, sanctions, or exclusion from federal health care programs could have a material adverse effect on our business, financial position and results of operations. From time to time we conduct routine reviews of our government pricing calculations. These reviews may have an impact on government price reporting and rebate calculations used to comply with various government regulations regarding reporting and payment obligations.
Paragraph 37 · 43% changed Every version of it
Market perceptions of Our success depends on how the market views our business are very important to us, especially market perceptions of Company and the safety and quality of our products. Incidents of product misuse may occur, and these events, among others, could result in additional regulatory controls (including requirements for additional labeling and REMS programs), product recalls, and product liability actions, and result in additional political, regulatory, and other scrutiny. The reporting of adverse safety events involving our products, including instances of product misuse, and public perceptions about such events, could cause our product sales to decline or experience periods of volatility. If any of our products or similar products that other companies distribute are subject to market withdrawal or recall or misused or are proven to be, or are claimed to be, harmful to consumers, and if any negative publicity associated with any of the foregoing occurs, then this could have a material adverse effect on our reputation, business, results of operations operations, and financial condition. Also, because our business is dependent on market perceptions, negative publicity associated with product quality, illness or other adverse effects resulting from, or perceived to be resulting from, our products could have a material adverse impact on our business, results of operations and financial condition.
Paragraph 36 · 41% changed Every version of it
Our business is highly dependent on market perceptions of us and the safety and quality of our products. Our business, products or product pricing could be subject to negative publicity, which could have a material adverse effect on our business, results of operations and financial condition.
Paragraph 71 · 41% changed Every version of it
There are a number of risks and uncertainties associated with clinical trials. The results of clinical trials may not be indicative of results that would be obtained from large scale testing. Clinical trials are often conducted with patients having advanced stages of disease and, as a result, during the course of treatment these patients can die or suffer adverse medical effects for reasons that may not be related to the pharmaceutical agents being tested, but which nevertheless affect the clinical trial results. In addition, side effects experienced by the patients may cause delay of approval or limit the profile of an approved product. Moreover, our clinical trials may not demonstrate sufficient safety and efficacy to obtain approval from the FDA or foreign regulatory authorities. The FDA or foreign regulatory authorities may not agree with our assessment of the clinical data or they may interpret it differently. Such regulatory authorities may require additional or expanded clinical trials. Even if the FDA or foreign regulatory authorities approve certain products developed by us, we cannot provide assurance that such regulatory authorities will not subject marketing of such products to certain limits on indicated use.
Paragraph 192 · 36% changed Every version of it
As of December 31, 2024, the Amneal Group controlled the majority of the voting power of all of our outstanding shares of common stock. Accordingly, the Amneal Group has substantial influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation, or sale of all or substantially all of our assets or any other significant corporate transactions. These stockholders may also delay or prevent preventing a change of control of the Company, even if such a change of control would benefit our other stockholders. This concentrated control could discourage a potential investor from seeking to acquire Class A common stock and, as a result, might harm the market price of that Class A common stock.
Paragraph 128 · 35% changed Every version of it
drug lists, and the process, criteria and timeframe for obtaining placement on the preferred drug list varies from state to state. Under the Medicaid drug rebate program, a manufacturer must pay a rebate for Medicaid utilization of a product. The rebate for single source products (including authorized generics) is based on the greater of (i) a specified percentage of the product’s average manufacturer price or (ii) the difference between the product’s average manufacturer price and the best price offered by the manufacturer. The rebate for multiple source products is a specified percentage of the product’s average manufacturer price. In addition, many states have established supplemental rebate programs as a condition for including a drug product on a preferred drug list. The profitability of our products may depend on the extent to which they appear on the preferred drug lists of a significant number of state Medicaid programs and the amount of the rebates that must be paid to such states. In addition, there There is significant fiscal pressure on the Medicare and Medicaid program, programs, and the introduction and enactment of new laws and amendments to existing laws to lower the pharmaceutical costs of the program are possible. Such laws and amendments could materially adversely affect our anticipated revenues and results of operations. For example, enacted in July 2025, OBBBA contains provisions that may reduce future Medicare reimbursement rates due to deficit-driven sequestration provisions. Similarly, certain provisions contained in OBBBA may have the effect of reducing participation in Medicaid on a national basis. Changes to Medicaid eligibility or enrollment procedures could reduce the number of covered individuals and decrease demand for our products. Due to the uncertainties regarding the outcome of future healthcare reform initiatives and their enactment and implementation, we cannot predict which, if any, of the future reform proposals will be adopted or the effect such adoption may have on our business. Future rulemaking and reform, including repeal of existing laws, including healthcare reform laws, with respect to the healthcare and pharmaceutical industries, could increase rebates, reduce prices or the rate of price increases for healthcare products and services, or require additional reporting and disclosure. We cannot predict the timing or impact of any future rule making, reform or repeal of healthcare laws.

MD&A

105 paragraphs · 13 new · 59 reworded · 10 gone · 10-K Feb 27, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 43 · 50% changed
Net revenue Other operating income for the year ended December 31, 2024 increased 16.7% 2025 was primarily comprised of income earned from the prior year primarily due to: PLI Scheme.
Paragraph 95 · 50% changed
For the year ended December 31, 2025, we recognized $22.8 million of intangible asset impairment charges in cost of goods sold. The charges primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application. For the year ended December 31, 2024, intangible asset impairment charges were not material. For the year ended December 31, 2023, we recognized $66.9 million of intangible asset impairment charges, of which $36.1 million was recognized in cost of goods sold and $30.8 million was recognized in in-process research and development impairment charges. Cost of sales impairment charges for the year ended December 31, 2023 of $36.1 million primarily related to a reduction in promotional focus on LYVISPAH™ in our Specialty segment, resulting in significantly lower than expected future cash flows. IPR&D impairment charges for the year ended December 31, 2023 of $30.8 million were related to one Affordable Medicines asset and one Specialty asset, both of which experienced adverse clinical trials results in the fourth quarter of 2023 and resulted in significantly lower than expected future cash flows.
Paragraph 71 · 49% changed
Net cash provided by operating activities was $295.1 $340.0 million for the year ended December 31, 2024 2025 as compared to $345.6 $295.1 million for the prior year. The year-over-year decrease in net operating cash flows for Excluding the year ended December 31, 2024 as compared to the prior year period was primarily driven by (i) lower collections of outstanding accounts receivable due to timing of sales in the quarter ended December 31, 2022, which benefited the year ended December 31, 2023 and (ii) receipt of a $21.4 $52.4 million upfront payment associated with the license agreement with Orion Corporation during the year ended December 31, 2023, partially offset by (i) increased profitability adjusted for non-cash items, (ii) lower period over period payments associated with the Opana ER® antitrust litigation settlement payment made in the prior year, net cash from operating activities decreased year-over-year as increases in cash earnings and (iii) favorable lower interest rates in the current year were more than offset by changes in working capital movements, most notably an increase in days payables outstanding. capital.
Paragraph 26 · 45% changed
•Growth in our Specialty segment of $55.3 million $82.8 million, primarily driven by a $44.7 increases of $58.1 million increase in our promoted Parkinson’s franchise, and $23.7 million of which $16.6 million was comprised of sales of ONGENTYS®, which launched in January 2024, CREXONT® and initial sales of CREXONT®, which launched in September 2024. Additionally, UNITHROID®, respectively, and growth in our promoted endocrinology portfolio of $20.8 million non-promoted products. This growth was partially offset by declines a year-over-year decrease of $6.0 million in our non-promoted products. out-licensing revenue associated with IPX203.
Paragraph 89 · 43% changed
In order to test goodwill for impairment, an entity is permitted to first assess qualitative factors to determine whether When a quantitative assessment of goodwill is necessary. The qualitative factors that we consider may include, but are not limited to, general economic conditions, our outlook, market performance of our industry and recent and forecasted financial performance. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. If a quantitative assessment test is required, we determine estimate the fair value of our each reporting unit using a combination of the income and market approaches. If the net book value of the reporting unit unit’s carrying amount exceeds its fair value, we recognize record a goodwill impairment charge for the reporting unit equal to the lesser of (i) the total amount of goodwill allocated to that reporting unit and or (ii) the amount by which that the reporting unit’s carrying amount exceeds its fair value.
Paragraph 46 · 41% changed
Specialty cost of goods sold for the year ended December 31, 2024 decreased 5.3% 2025 increased 21.2% as compared to the prior year primarily due to a marketed product intangible asset an impairment charge of $34.1 million in 2023 related to reduced promotional focus on LYVISPAH®, partially offset by a non-promoted product of $22.1 million (refer to Note 11. Goodwill and Other Intangible Assets for additional information) and increased sales in our promoted products. Specialty gross profit as a percentage of net revenue increased to 54.5% for the year ended December 31, 2024 as compared to 45.1% in the prior year as a result of the factors described above. volume and product mix.
Paragraph 57 · 41% changed
Over the next 12 months, we expect to make substantial payments for monthly interest and quarterly principal amounts due for our Term Loan Due 2028, monthly 2032, semi-annual interest payments on our Amended New Credit Facility, Senior Notes Due 2032, and contractual payments for leased premises. In January 2025, the Company paid the entire remaining principal balance Refer to Note 14. Debt, Note 16. Leases, and Commitments and Contractual Obligations under Part II, Item 7. Management’s Discussion and Analysis of $192.0 million outstanding on its Term Financial Condition and Results of Operations for additional information.
Paragraph 65 · 40% changed
Pursuant to a development licensing and supply agreement with Kashiv Biosciences LLC (“Kashiv”) mAbxience S.L. (“mAbxience”) for a long-acting injectable, we two denosumab biosimilars referencing Prolia® and XGEVA®, the Company paid Kashiv $10.0 mAbxience $7.5 million in February 2025 for 2026 upon the achievement of a regulatory milestone, which was milestones. These amounts had been accrued as of December 31, 2024. 2025. Refer to Note 23. Related Party Transactions 4. Alliance and Collaboration for additional information.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors215 words changed in this paragraph; it is 72% similar to last year's version.
These changing rules, regulations and stakeholder expectations have resulted in, and are likely to continue to result in, uncertainty, increased general and administrative expenses and increased management time and attention spent complying with or meeting such regulations and expectations. For example, in 2023 the State of California recently passed the Climate Corporate Data Accountability Act and the Climate-Related Financial Risk Act that will Act, laws which would, if they survive an ongoing legal challenge, impose broad climate-related disclosure obligations on certain companies doing business in California, including us. Other U.S. states’ legislatures are considering enactment of similar rules and regulations. In addition, the European Union (“EU”) enacted the Corporate Sustainability Reporting Directive (“CSRD”) legislation in January 2023 which requires certain reporting and disclosure starting during the first quarter of 2026 of calendar year 2025 data relating to ESG sustainability matters for companies whose business and assets exceed certain thresholds within EU countries. Due countries, including non-EU groups with EU subsidiaries. During 2025, CSRD was subject to proposals that, when adopted (which is expected during 2026), would significantly reduce the scope and substance of the reporting obligations; however, due to our subsidiaries in Ireland, the CSRD CSRD’s so-called “third country” requirements will may apply to us for 2025 reporting, reporting in 2029 in respect of the 2028 financial year, depending on the level of revenue generated by such subsidiaries, which will would require significant preparatory work to comply with the reporting rules. Developing and acting on initiatives within the scope of ESG, sustainability, and collecting, measuring and reporting ESG related sustainability-related information and metrics can be costly, difficult and time consuming and is subject to evolving reporting standards and similar differing proposals offered by other international various regulatory bodies. We may also communicate certain initiatives and goals, goals regarding environmental matters, diversity, workforce management and talent retention, responsible sourcing and sourcing, social investments and or other ESG related matters, sustainability-related matters in our responsible business report or other public disclosures. documents. These initiatives and goals within the scope of ESG could be difficult and expensive to implement, the technologies needed to implement them may not be cost effective and may not advance at a sufficient pace, and we could be criticized for the accuracy, adequacy or completeness of the disclosure. Further, statements about our ESG-related sustainability-related initiatives and goals, and progress against those goals, may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. In addition, we could be criticized for the scope or nature of such initiatives or goals, for any revisions to these goals, or for failure to achieve such goals. If our sustainability-related data, processes and reporting are incomplete or inaccurate, or if we fail to achieve progress with respect to these goals on a timely basis, or at all, our reputation, business, financial performance and growth could be adversely affected.

Source: Item 1A, 10-K 0001723128-26-000011 vs Item 1A, 10-K 0001723128-25-000012

MD&A173 words changed in this paragraph; it is 34% similar to last year's version.
Net cash used in financing activities of $211.8 $31.5 million for the year ended December 31, 2024 was relatively flat 2025 as compared to $211.8 million for the prior year as a decrease in payments associated with refinancing our Term Loan Due 2025 in the prior year of $162.3 million and a reduction in tax distributions paid to non-controlling interests of $51.1 million were offset by a year. The year-over-year decrease in net cash used in financing activities was primarily due to a net increase in cash inflows from debt of $167.3 million, primarily as a result of the refinancing of our debt in the current year (refer to Note 14. Debt), repayment of notes payable - related party of $44.2 million in the prior year, and financing leases cash received from an alliance party of $207.8 $6.4 million in the current year, partially offset by an increase of $24.0 million in tax and other cash and other distributions to non-controlling interests and an increase in employee payroll tax withholding withholdings on restricted stock unit and performance stock unit vesting of $5.6 $14.3 million. Refer to Note 15. Debt for additional information about the refinancing our Term Loan Due 2025. The decrease in tax distributions was the result of the Reorganization (refer to Note 21. Stockholders’ (Deficiency) Equity for additional information).

Source: Item 7, 10-K 0001723128-26-000011 vs Item 7, 10-K 0001723128-25-000012

Legal Proceedings144 words changed in this paragraph; it is 52% similar to last year's version.
Beginning in 2020, Amneal was named as a defendant in several putative class action lawsuits filed and consolidated in the United States District Court for the District of New Jersey, seeking compensation for economic loss allegedly incurred in connection with their purchase of generic metformin allegedly contaminated with NDMA. See In Re Metformin Marketing and Sales Practices Litigation (No. 2:20-cv-02324-MCA-MAH) (“In re Metformin”), Marcia E. Brice v. Amneal Pharmaceuticals, Inc., No. 2:20-cv-13728 (D.N.J.), and Michael Hann v. Amneal Pharmaceuticals of New York, LLC et al., No. 2:23-cv-22902 (D.N.J.). Metformin”). On January 7, 2025, 30, 2026, the court dismissed the Third Amended Complaint Court issued an Order granting in In Re Metformin without prejudice part and granted plaintiffs the opportunity to amend their complaint. On February 20, 2025, plaintiffs filed a Fourth Amended Complaint denying in In Re Metformin, which incorporated the allegations of plaintiff Brice and plaintiff Hann, and then filed notices of voluntary dismissal of Marcia E. Brice v. Amneal Pharmaceuticals, Inc., No. 2:20-cv-13728 (D.N.J.) and Michael Hann v. Amneal Pharmaceuticals of New York, LLC et al., No. 2:23-cv-22902 (D.N.J.) as standalone actions. Defendants will file a part Defendants’ motion to dismiss the Fourth Amended Complaint by March 7, 2025. Plaintiffs’ response in opposition Complaint. Discovery is due on April 7, 2025 and defendants’ reply is due on April 22, 2025. ongoing.

Source: Item 3, via Note 19 – Commitments and Contingencies, 10-K 0001723128-26-000011 vs Item 3, via Note 20 – Commitments and Contingencies, 10-K 0001723128-25-000012

Accounting Policies129 words changed in this paragraph; it is 34% similar to last year's version.
The Company has operations in the U.S., India, Ireland, and other foreign jurisdictions. Generally, the Company’s foreign operating subsidiaries’ functional currency is the local currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Translation adjustments are included in accumulated other comprehensive (loss) income and non-controlling interests in the consolidated balance sheets and are included in comprehensive loss. Transaction gains and losses are included in net loss in the Company’s consolidated statements of operations as a component of foreign exchange (loss) gain, net. Such foreign currency transaction gains and losses include fluctuations related to long-term intercompany loans that are payable in the foreseeable future. Translation gains and losses on intercompany balances of a long-term investment nature are included in foreign currency translation adjustments in accumulated other comprehensive (loss) income and non-controlling interests, and comprehensive loss.

Source: 10-K text, Note 2 – Summary of Significant Accounting Policies, 10-K 0001723128-26-000011 vs 10-K text, Note 2 – Summary of Significant Accounting Policies, 10-K 0001723128-25-000012

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of AMRX's Risk Factors and MD&A, 10-K Feb 27, 2026 against 10-K Feb 28, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
We are subject to certain trade and tariff requirements imposed by the U.S. and various foreign governments. The great majority of our net sales rely on finished dosage forms (“FDF”) or API produced in the U.S. or India. We have limited reliance on imports from Europe and China, and no reliance on imports from Mexico or Canada.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Since taking office in 2025, President Trump has announced a number of tariff actions, and while there are currently no reciprocal tariffs on pharmaceutical products imported into the U.S., this can change at any moment. On February 1, 2025, the Administration imposed a 10% tariff on all products from China under the International Emergency Economic Powers Act, (50 U.S.C. 1701 et seq) (the “IEEPA”), and related authorities as announced in the Federal Register Notice and Executive Order 14195 dated February 1, 2025 (as amended). On February 20, 2026, the Supreme Court of the United States issued an opinion ruling that President Trump’s tariffs exceeded presidential authority under the IEEPA, which had the effect of invalidating the tariffs imposed thereunder to date.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
On April 14, 2025, the Department of Commerce Bureau of Industry and Security (“DOCBIS”) announced that it had initiated, as of April 1, 2025, a broad investigation under section 232 of the Trade Expansion Act to determine the effects on national security of imports of pharmaceuticals (i.e. FDF, API, key starting materials, derivatives, and medical countermeasures), including whether trade remedies such as tariffs should be imposed. This investigation covers both generic and brand products. On September 26, 2025, DOCBIS announced that it had initiated, as of September 2, 2025, a separate Section 232 national security investigation of imports of personal protective equipment, medical consumables (including syringes and intravenous bags), and medical equipment (including devices). These Section 232 investigations are ongoing. On February 20, 2026, President Trump imposed a 10% global tariff for 150 days under Section 122 of the Trade Act of 1974. FDF and API are exempt from the Section 122 tariff as of the date of this filing.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Given the global nature of pharmaceutical supply chains, any changes to historically prevailing tariff requirements could impact us and our industry by increasing costs, affecting product availability, and/or disrupting supply chains. The Company is closely monitoring these tariff and trade developments, which remain uncertain and unpredictable.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
We rely heavily on timely interactions with the FDA, the DEA, and other agencies of the U.S. federal government for, among other things, new product reviews and approvals, procurement quotas for controlled substances, facility inspections, and regulatory guidance. During a government shutdown, delays in these interactions could negatively impact our regulatory, operational and financial performance.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Additionally, our AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs. Interruptions in government contracting and procurement processes, and slower payment cycles to distributors which AvKARE uses to do business with these governmental agencies, could also negatively impact our operational and financial performance.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
We rely on information technology systems for critical functions, including supply chain management, transaction processing, finance, human resources, sales order management, compliance, and reporting. In 2025, we began a multi-year enterprise resource planning (“ERP”) system implementation for certain parts of our business to integrate and modernize these processes. If the ERP system is not implemented as planned or does not operate effectively, it could disrupt operations, increase costs, and impair our ability to manage our business and maintain effective internal control over financial reporting.
Read it in 10-K Feb 27, 2026 at sec.gov
Show the other 64
AddedRisk Factors
We rely on our internal technology systems and websites to run our business as well as our or our third-party partners’ physical facilities, such as our R&D or manufacturing premises. In addition, we rely on third-party hosted services. A disruption, infiltration or failure of these systems, facilities or third-party hosted services in the event of a hurricane, tsunami, tornado,
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Escalating geopolitical tensions or military conflict between India and Pakistan could disrupt our operations, supply chain, or workforce in the region, potentially resulting in production delays, increased costs, or reduced availability of key materials. Any sustained instability in the region could also impair our ability to maintain reliable logistics, regulatory continuity, or business continuity planning across affected jurisdictions.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
The recently enacted OBBBA introduces significant changes to U.S. healthcare programs, including Medicaid, Medicare, and Affordable Care Act marketplaces. These changes may reduce federal healthcare spending and alter eligibility requirements, which could result in fewer individuals having health coverage. Reduced coverage could lead to lower prescription volumes and decreased demand for our products. Additionally, OBBBA includes provisions that may increase compliance obligations and administrative complexity for manufacturers participating in government programs. These changes could require additional resources and may increase our costs. The full impact of OBBBA is uncertain and will depend on implementation details and potential state-level actions. These developments could adversely affect our business, results of operations, or financial condition.
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedRisk Factors
Revenues and gross margin derived from generic pharmaceutical products often follow a pattern based on regulatory and competitive factors that we believe are unique to the generic pharmaceutical industry. As the patent(s) for a brand name product
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
We depend to a large extent on third-party suppliers and distributors for the raw materials for our products, particularly the chemical compounds comprising the APIs that we use to manufacture our products, as well as for certain finished goods. A prolonged interruption in the supply of such products could have a material adverse effect on our business, financial position and results of operations.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
The U.S. and various foreign governments have established certain trade and tariff requirements. From time to time, the U.S. government has indicated a willingness to revise or renegotiate tariffs on certain goods imported into the U.S. Since we rely on APIs, packaging and other components and finished pharmaceutical products from China, India, and certain countries in the European Union, such steps, if adopted, could adversely impact our business, increase our costs, and make our products less competitive.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
On February 1, 2025, President Trump announced a 10% additional tariff on imports from China and has expressed the possibility of imposing tariffs on imports from the European Union and India. In addition, on February 13, 2025, President Trump announced a plan to establish reciprocal tariffs with nations that impose tariffs on U.S. products, and directed relevant segments of the U.S. government to assess harm of non-reciprocal trade arrangements and to generate a report of that assessment within 180 days. Reciprocal tariffs may be imposed prior to completion of the report. There also have been statements by the Trump Administration regarding a 25% tariff on pharmaceutical products. For the year ending December 31, 2025, we estimate the impact of tariffs currently imposed on our imports from China will not be material. We are unable to estimate the impacts of any tariffs that have not yet been imposed by the U.S. government.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Maintaining the secrecy of confidential, proprietary, and/or trade secret information is important to our competitive business position. We continually assess these threats and make investments to increase internal protection, detection, and response
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
subject to change in the future. In addition, we could be criticized for the scope or nature of such initiatives or goals, or for any revisions to these goals. If our ESG-related data, processes and reporting are incomplete or inaccurate, or if we fail to achieve progress with respect to our goals within the scope of ESG on a timely basis, or at all, our reputation, business, financial performance and growth could be adversely affected.
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedRisk Factors
The pharmaceutical industry has We also in recent years been the subject face risks resulting from public criticism of significant publicity regarding the drug pricing of pharmaceutical products more generally, including publicity and pressure resulting from prices charged by competitors and peer companies for new products as well as price increases by competitors and peer companies on older products that the public has deemed excessive.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
The majority of our products are produced at a limited number of locations, and a business interruption at one or more of these locations or within our supply Supply chain disruptions could have a material adverse effect on our business, financial position and results of operations.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
As of December 31, 2024, 2025, we had $2.6 $2.7 billion of total indebtedness, comprised of $2.3 billion, $192.0 million $2.1 billion and $100.0 $600.0 million in borrowings outstanding on the Term Loan Due 2028, Term Loan 2032 and Senior Notes Due 2025 and Amended New Revolving Credit Facility, 2032, respectively.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We are a party to a tax receivable agreement (“TRA”) with each of the members of the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (“Members” or the “Amneal Group”), dated May 4, 2018. Group.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We may also communicate certain initiatives and goals, goals regarding environmental matters, diversity, workforce management and talent retention, responsible sourcing and sourcing, social investments and or other ESG related matters, sustainability-related matters in our responsible business report or other public disclosures. documents.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We may experience Customer consolidation could cause declines in the sales volume and the prices of our products as a result of the continuing trend of consolidation of certain customer groups, products, which could have a material adverse effect on our business, financial position and results of operations.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
As of December 31, 2024, 2025, we had an ability to borrow up to an additional $523.2 $678.2 million under our revolving credit facilities, comprised of $495.2 $595.2 million and $28.0 $83.0 million of available capacity under the Amended New 2025 Revolving Credit Facility (as defined and the Amended Rondo Revolving Credit Facility, respectively. described in Note 14.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We generally begin our development activities for Developing a new generic drug product often starts several years in advance of the patent expiration date of before the brand-name drug equivalent. equivalent patent expires.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
If we are unable to timely obtain these licenses on commercially reasonable terms, our ability to commercially market our products may be inhibited or prevented, which could have a material adverse effect on our business, results of operations and financial condition.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
The “Pillar One” global profit allocation proposal would not apply currently applies only to us, because it the largest and most profitable multinational enterprises and, as proposed, generally applies to companies with global revenues exceeding €20 billion (approximately $21 $23 billion using the exchange rate as of December 31, 2024). 2025).
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
In addition, the European Union (“EU”) enacted the Corporate Sustainability Reporting Directive (“CSRD”) legislation in January 2023 which requires certain reporting and disclosure starting during the first quarter of 2026 of calendar year 2025 data relating to ESG sustainability matters for companies whose business and assets exceed certain thresholds within EU countries. countries, including non-EU groups with EU subsidiaries.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We expect to make interest payments totaling $226.9 $193.9 million, excluding the impact of our interest rate swap and borrowings under our Amended New Revolving Credit Facility, swap, during 2025 2026 related to the Term Loan Due 2028. 2032 and Senior Notes Due 2032.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
For example, in 2025, we expect to lose lost exclusivity for RYTARY®, an extended-release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
The Amneal Group has control significant influence over all matters submitted to our stockholders for approval, including changes in capital structure, transactions requiring stockholder approval under Delaware law and corporate governance, subject to the terms of the Stockholders Agreement relating to the Amneal Group's agreement to vote in favor of directors not designated by the Amneal Group and such other matters that are set forth in the Stockholders Agreement.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
poisoning in adults. RYTARY® is indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. UNITHROID®, indicated for the treatment of hypothyroidism, is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
New product launches are an important growth driver. Brekiya® autoinjector, approved by the FDA in May 2025 and launched in the U.S. in October 2025, is the first and only ready-to-use autoinjector formulation of dihydroergotamine mesylate indicated for the acute treatment of migraine, with or without aura, and for the acute treatment of cluster headache in adults.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
In 2025, CREXONT® continued to grow within our Specialty segment. CREXONT® was added to three large national formularies, which expanded total U.S. insurance coverage from about 30% of covered lives at the end of 2024 to over 50% at the end of 2025. In December 2025, we announced new positive interim results from our ongoing Phase 4 ELEVATE-PD study, including significant increases in daily “Good On” time and reductions in “Off” time.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
We are subject to certain trade and tariff requirements imposed by the U.S. and various foreign governments. The great majority of our net sales rely on FDF or API produced in the U.S. or India. We have limited reliance on imports from Europe and China, and no reliance on imports from Mexico or Canada.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Since taking office in 2025, President Trump has announced a number of tariff actions, and while there are currently no reciprocal tariffs on pharmaceutical products imported into the U.S., this can change at any moment. On February 1, 2025, the Administration imposed a 10% tariff on all products from China under the International Emergency Economic Powers Act, (50 U.S.C. 1701 et seq) (the “IEEPA”), and related authorities as announced in the Federal Register Notice and Executive Order 14195 dated February 1, 2025 (as amended). On February 20, 2026, the Supreme Court of the United States issued an opinion
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
On April 14, 2025, the Department of Commerce Bureau of Industry and Security (“DOCBIS”) announced that it had initiated, as of April 1, 2025, a broad investigation under section 232 of the Trade Expansion Act to determine the effects on national security of imports of pharmaceuticals (i.e. FDF, API, key starting materials, derivatives, and medical countermeasures), including whether trade remedies such as tariffs should be imposed. This investigation covers both generic and brand products. On September 26, 2025, DOCBIS announced that it had initiated, as of September 2, 2025, a separate Section 232 national security investigation of imports of personal protective equipment, medical consumables (including syringes and intravenous bags), and medical equipment (including devices). These Section 232 investigations are ongoing. On February 20, 2026, President Trump imposed a 10% global tariff for 150 days under Section 122 of the Trade Act of 1974. FDF and API are exempt from the Section 122 tariff as of the date of this filing.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Given the global nature of pharmaceutical supply chains, any changes to historically prevailing tariff requirements could impact us and our industry by increasing costs, affecting product availability, and/or disrupting supply chains. The Company is closely monitoring these tariff and trade developments and will take actions to reduce or minimize any material negative impact.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
On July 4, 2025, President Trump signed OBBBA, which includes a broad range of tax reform provisions affecting businesses, including, but not limited to, extending or making permanent certain business and international tax measures initially established under the 2017 Tax Cuts and Jobs Act and eliminating the requirement to capitalize and amortize U.S.-based research and experimental expenditures over five years, making these expenditures fully deductible in the period incurred. These provisions resulted in a reduction of the Company’s current income tax liabilities of $7.8 million during the year ended December 31, 2025.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Other operating income for the year ended December 31, 2025 was primarily comprised of income earned from the India Production Linked Incentive Scheme for the Pharmaceutical Sector (the “PLI Scheme”).
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
On January 23, 2026, we determined that we will make effective our nationwide agreement to settle a substantial majority of the opioids-related claims brought against us by various states and subdivisions (the “Nationwide Opioids Settlement Agreement”), having previously secured sufficient participation by those states and subdivisions, including all eligible state and territorial Attorneys General and all subdivisions that previously sued us. The Nationwide Opioids Settlement Agreement was effective on January 29, 2026 and we made our first installment payment of $23.8 million to the trust administrator on that date. An additional installment payment of $12.1 million was made on February 26, 2026. Refer to Note 19. Commitments and Contingencies and Note 25. Subsequent Events for additional information.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Beginning on January 1, 2026, the holders of the Rondo Class B Units have a put right to require us to purchase their units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization subject to
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedMD&A
Although we had a minority economic interest in Amneal prior to March 31, 2023, we were Amneal’s sole managing member, having the sole voting power to make all of Amneal’s business decisions and control its management. Therefore, we consolidated the financial statements of Amneal and its subsidiaries prior to the Reorganization. We recorded non-controlling interests for the portion of Amneal’s economic interests that we did not hold prior to the Reorganization.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
During the fourth quarter of 2024, we changed the name of our Generics segment to “Affordable Medicines” to reflect the full product offering of the segment. The segment name change did not result in any change to the composition of our reportable segments and, therefore, did not result in any changes to our historical segment results.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
In process research and development (“IPR&D”) impairment charges of $30.8 million for the year ended December 31, 2023 were related to one Affordable Medicines asset and one Specialty asset, both of which experienced adverse clinical trials results in the fourth quarter of 2023 and resulted in significantly lower than expected future cash flows.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
The year-over-year variance of $13.6 million in change in fair value of contingent consideration for the year ended December 31, 2024 as compared to the prior year was primarily related to a reduction in promotional focus on LYVISPAHTM during the year ended December 31, 2023. Refer to Note 18. Fair Value Measurements for additional information.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
Affordable Medicines IPR&D impairment charges for the year ended December 31, 2023 were related to one asset that experienced adverse clinical trials results in the fourth quarter of 2023 and resulted in significantly lower than expected future cash flows.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
For the year ended December 31, 2023, the Affordable Medicines credit related to legal matters, net was $(0.1) million, comprised of $10.0 million received from the settlement of patent infringement matters, net of $3.9 million in charges associated with civil prescription opioid litigation, a $3.0 million charge for the settlement of a customer claim, and a $3.0 million charge for the settlement of commercial antitrust litigation.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
The year-over-year variance of $13.6 million in change in fair value of contingent consideration for the year ended December 31, 2024 as compared to the prior year was primarily related to a reduction in promotional focus on LYVISPAHTM during the year ended December 31, 2023. Refer to Note 18. Fair Value Measurements for additional information.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
(2)A description of our Amended New Revolving Credit Facility is contained in Note 15. Debt. The table assumes the balance outstanding as of December 31, 2024 will be repaid or refinanced by December 31, 2025. The actual balance outstanding may fluctuate significantly in future periods. The interest rate on borrowings under the Amended New Revolving Credit Facility resets every 30, 90 or 180 days based on the term that we select. In January 2025, the Company paid the entire remaining principal balance of $192.0 million outstanding on its Term Loan Due 2025, plus accrued interest thereon of $0.7 million, with $190.0 million of new borrowings under the Amended New Revolving Credit Facility and cash on hand.
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedMD&A
AvKARE cost of goods sold for the year ended December 31, 2024 2025 increased 25.7% 6.9% as compared to the prior year, and gross profit as a percentage of net revenue decreased to 15.6% for the year ended December 31, 2024 from 16.3% in the prior year primarily due to the higher sales in our government label channel and an increase in our inventory provision, partially offset by decreased sales through in our lower margin distribution channel and an increased inventory provision. channel.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Specialty cost of goods sold for the year ended December 31, 2024 decreased 5.3% 2025 increased 21.2% as compared to the prior year primarily due to a marketed product intangible asset an impairment charge of $34.1 million in 2023 related to reduced promotional focus on LYVISPAH®, partially offset by increased sales in our promoted products. a non-promoted product of $22.1 million (refer to Note 11.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The year-over-year decrease increase in net cash used in investing activities was primarily due to $12.0 million an increase in capital expenditures and deposits for future acquisition of property, plant, and equipment in the current year, partially offset by proceeds from the sale of a subsidiary in India to a subsidiary of Kashiv in April 2024 (refer to Note 23. the prior year.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Research and development (“R&D”) expenses for the year ended December 31, 2024 increased 16.3% 2025 decreased 2.4% from the prior year primarily due to an increase a decrease in in-licensing and upfront milestone payments of $30.0 $7.5 million, including $20.0 million associated with our exclusive license of Omalizumab (refer to Note 23. partially offset by an increase in employee compensation.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Specialty Affordable Medicines R&D expense for the year ended December 31, 2024 2025 decreased 40.3% 9.2% as compared to the prior year primarily due to reduced project spend decreases in in-licensing and upfront milestone payments of $8.6 $13.5 million and reduced infrastructure costs. project spend, partially offset by increased employee compensation.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
We test goodwill for possible Goodwill is not amortized; rather, it is subject to annual impairment annually testing during the fourth quarter, quarter of each year, or whenever more frequent testing if events or circumstances indicate that the carrying amount may not be recoverable.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Further testing is only required if the entity determines, If, based on the qualitative this assessment, we conclude that it is more likely than not that a reporting unit’s fair value is less than exceeds its carrying amount. amount, no further testing is required.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Specialty SG&A expense Selling, general and administrative (“SG&A”) expenses for the year ended December 31, 2024 2025 increased 24.4% 10.6% as compared to the prior year primarily due to increases in promotional employee compensation and launch costs associated with ONGENTYS® CREXONT® and CREXONT®. the Brekiya® autoinjector.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Affordable Medicines net revenue for the year ended December 31, 2024 2025 increased 14.5% 3.6% as compared to the prior year, primarily due to new products launched in 2024 2025 and 2023, 2024, which included biosimilars that contributed $59.7 million of year-over-year growth and other new products that contributed $144.1 $122.6 million of year-over-year growth, and strong volume growth, partially offset by price erosion.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Specialty Affordable Medicines SG&A expense for the year ended December 31, 2024 2025 increased 24.4% as by 9.9% compared to the prior year primarily due to increases in promotional employee compensation, costs associated with ONGENTYS® of our international expansion, and CREXONT®. shipping costs.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Specialty R&D expense for the year ended December 31, 2024 decreased 40.3% 2025 increased 59.2% as compared to the prior year primarily due to reduced project spend increased in-licensing and upfront milestone payments of $8.6 $6.0 million and reduced infrastructure costs. higher project spend.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Further testing is only required if the entity determines, based on the We may first perform a qualitative assessment, that assessment to determine whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesMD&A
Our Affordable Medicines segment includes approximately 270 over 280 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals.
Read it in 10-K Feb 27, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AMRX/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.